An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine

Status Completed

Clinical Trial Summary

Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO. Reduction of NOS, and therefore NO, may be an effective technique for the treatment of migraine headache. GW274150 is a highly selective inhibitor of NOS and offers the potential of anti-inflammatory activity in migraine through a novel mechanism of action. The intent of this study is to investigate the safety and efficacy of GW274150 for the acute treatment of migraine headache.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00319137
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 2
Start date	December 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06192173` - Patent Foramen Ovale Closure in Migraine
Completed	`NCT05525611` - Cabergoline as a Preventive Treatment for Chronic Migraine	N/A
Recruiting	`NCT03832998` - Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine	Phase 3
Enrolling by invitation	`NCT04196933` - Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma	N/A
Not yet recruiting	`NCT06428838` - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context	Phase 3
Completed	`NCT06304675` - Manageable Environmental Factors in Migraine
Completed	`NCT04084314` - Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study	Phase 4
Recruiting	`NCT05517200` - Pilot Study for a Machine Learning Test for Migraine
Completed	`NCT04179474` - Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine	Phase 1
Recruiting	`NCT04603976` - Registry for Migraine - Clinical Core	Phase 4
Completed	`NCT03597529` - CHOCOlate MeLatonin for AdolescenT MigrainE	Phase 2
Completed	`NCT04197349` - Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman	Phase 1
Recruiting	`NCT05891808` - miR-155 Expression in Episodic and Chronic Migraine
Active, not recruiting	`NCT05064371` - Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan	Phase 3
Suspended	`NCT04069572` - Vibratory Stimulation for the Treatment of Chronic Pain	N/A
Not yet recruiting	`NCT04859374` - Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach	N/A
Not yet recruiting	`NCT03083860` - Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.	N/A
Completed	`NCT02905227` - A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder	Phase 1
Enrolling by invitation	`NCT02532023` - The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients	Phase 4
Completed	`NCT02108678` - One-Day Intervention for Depression and Impairment in Migraine Patients	N/A